NEW PRODUCT
PLANNING AND COMMERCIAL STRATEGY
GNG Group’s in-depth experience, across diverse therapeutic areas, including rare diseases and potential first-in-market medicines, allows us to deliver a rigorous analysis with a rapid response, even in situations with limited data, budget and timeframe.
IN-LICENSING
ASSESSMENTS
GNG Assessments include:
-
Strategic scenario planning and evaluation.
-
Support for investment decisions.
-
Advanced statistical modeling & analytics.
-
Thorough review of numerous sales & NPV paths.
-
Pricing strategy and much more.
“We help maximize the value of new products to physicians, payers and patients.”
- John McNally
New Product Commercial Maximization
Competitive intelligence
Pricing scenarios and analysis
Value proposition developed
Targeting
Refinements
Ongoing customer
and KOL feedback
Sales Force Size
& Marketing Plan
Incentive Compensation Design
Launch Strong
Incorporation of commercial and payer perspective before Phase 2 trial design is necessary for optimal success at launch.
For Example:
GNG can help you with early well-planned Phase 2 investments (e.g., inclusion of a comparator) to establish an optimal product reimbursement environment, resulting in significant incremental post-launch success.
Select GNG Maximization Components
-
Competitive intelligence: Profiles, launch dates and patent expirations of current & future competitors.
-
Strategic insights and likelihood assessments.
-
Value proposition: maximize differential advantage vs. competitors from physician, patient and payer perspective, for strong reimbursement.
-
Phase 2 trial design: ensure inclusion of comparator/patient-reported outcomes, sufficient duration & sample size to build commercial confidence, and establish go/no-go criteria.
-
Phase 3 trial design: ensure health outcome evidence aligned to support the target label.
-
Clinical, regulatory and scientific activities: ensure alignment with the target value proposition.
-
Key Opinion Leader (KOL) engagement and feedback on product strengths and weaknesses.